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Abstract
Sepsis refers to systemic inflammatory response syndrome and organ failure resulting from infection. Inflammatory
receptors (e.g., Toll-like receptors and nucleotide oligomerization domain) recognize bacterial components as
inflammatory ligands. These are expressed not only in leukocytes but also in major organs and vascular endothelial
cells. “Alert cell” is defined as the cell that expresses the inflammatory receptor and intracellular signaling system to
produce inflammatory mediators such as inflammatory cytokines, chemokines, nitric oxide, and prostanoids in
organs and the vasculature. NF-κB and AP-1, which are the transcriptional factors of these inflammatory molecules,
are important regulators of multiple organ failure in sepsis and systemic inflammation. The vascular endothelial
injury would induce multiple organ failure as tissue ischemia and organ death. Drug discovery targeted at alert cells
holds a promise for therapy of inflammation including sepsis.
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Introduction
Sepsis is a systemic inflammatory response syndrome
(SIRS) and/or leads to organ dysfunction due to infection.
An old definition of sepsis was a SIRS with infection in a
joint conference by the American College of Chest
Physicians and the Society of Critical Care Medicine in
1991 [1]. The septic clinical outcome has still been bad.
In-hospital mortality in septic shock is hardly satisfactory
over 20 % with high treatment cost in many countries in
2015. When indirect deaths that complicate chronic
conditions (e.g., cardiac failure, cancer) would be included,
over 50,000 people a year were estimated to die from
sepsis even in Japan. We need to seek the key issue to
solve the problem in the clinical management and drug
discovery.
In 2001, Angus et al. reported 751,000 deaths across
seven states in the USA due to increased severity of
sepsis, with a mortality rate of 28.6 % [2]. The “Surviving
Sepsis Campaign guidelines” were drafted to improve
survival in 2004 [3], with revisions published in 2008 [4]
and in 2013 [5]. Hospital mortality rates dropped 0.7 %
per site for every 3 months after the participation of the
Surviving Sepsis Campaign in 2004 [6]. And in Japan,
the Japanese Society of Intensive Care Medicine
published the Japanese guidelines [7] for the manage-
ment of sepsis. However, there was a large difference in
the outcome among the facilities in Japan.
There is currently no definitive drug for sepsis and
systemic inflammation with multiple organ failure except
for antimicrobial agents. This article will provide basic
point of view for the clinical management and future
drug discovery in sepsis and inflammation.
Review
Inflammatory receptors
The role of human Toll-like receptors (TLRs) and the
other inflammatory receptors has considerably advanced
to know since the several pioneering studies that dem-
onstrated a relationship between Toll receptors and nat-
ural immunity [8–11]. TLR, nucleotide oligomerization
domain (NOD), and NOD containing leucine-rich
repeats (NLRs) are recognized as one of receptors of
pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs) on mi-
croorganisms. The structures of the leucine-rich repeat
domain have been determined at NLRC4, NLRP1, and
NLRX1 in NLRs and at TLR1-5, TLR6, TLR8, and TLR9
in TLRs. Working out the intracellular signaling
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pathways downstream of these receptors has provided a
clearer picture of how systemic inflammation occurs in
sepsis and SIRS conditions [11, 12]. To this end, recent
studies have elucidated the signaling pathways down-
stream of receptors implicated in sepsis, including the
TNF receptor (TNF-R) [13, 14] and interleukin receptors
(e.g., IL-R1 [15, 16], IL-R6 [17, 18]). These led to a better
understanding of mechanisms underlying the propaga-
tion and amplification of inflammation between cells
after TLR stimulation.
While sepsis therapies have been pursued against many
different inflammatory mediators, these mediators can be
collectively considered products of transcriptional activa-
tion via inflammatory receptor signaling. In particular, the
mechanism of amplifying inflammation through the
transcription factors such as nuclear factor-κB (NF-κB)
and activator protein-1 (AP-1) is particularly important in
SIRS-induced vasculitis (SIVA) of vascular endothelium.
From the perspective of gene expression, which adds an
additional layer of complexity to sepsis, transcriptional
activity of NF-κB and AP-1 was focused in this manu-
script. It is considered that the pathophysiology accom-
panies the increase in sepsis severity at the cellular level
and discusses possibilities in new drug discovery.
The definition of alert cell and SIVA
The most important issue to induce multiple organ failure
in inflammation is the expression and location of inflam-
matory receptors (e.g., TLR, TNF-R, and IL-R) and the
intracellular signaling molecules on the various epithelial
cells and vascular endothelial cells. SIRS pathophysiology
was previously considered to result from infiltration of
leukocytes, such as neutrophils and dendritic cells, and
the overproduction of inflammatory cytokines. However,
this theory cannot completely explain why the earliest
organ symptoms of SIRS (e.g., acute lung injury and tachy-
cardia) are readily manifest and differ in the extent of
inflammation across major organs. Similar to leukocytes,
some epithelial cells in major organs express inflammatory
receptors on their surface and can produce inflammatory
mediators such as inflammatory cytokines, chemokines,
nitric oxide (NO), and prostanoids as “inflammatory alert
cells” (hereafter, alert cell) shown as Fig. 1 [19] . A 3,3′-di-
aminobenzidine and tetrahydrochloride staining revealed
TLR4 expression in alveolar epithelial type 2 cells, vascular
endothelial cells in lung (Fig. 1a) and in cardiomyocytes
and vascular endothelial cells in right atrium (Fig. 1b), and
the endocardium of the atrial septum (Fig. 1c). The alert
cell is defined as the inflammatory-response cell, which
can recognize ligands such as DAMPs and PAMPs in
tissues and produce chemokine and inflammatory mole-
cules. Vascular endothelial cell is one of the alert cells,
which can induce SIVA by recognizing several types of
ligands such as DAMPs and PAMPs and producing
inflammatory molecules and coagulation factors. The
SIVA is defined as an endothelial inflammation in SIRS.
Alert cell strategy is a cell-targeting protection therapy for
alert cells in systemic inflammation.
To date, many receptors that trigger inflammation
have been characterized as described above, including
TLR, TNF-R, IL-1R, NOD, NLR, C-type lectin receptor
(CLR), receptor for advanced glycation end product
(RAGE) [20, 21], and protease-activated receptor (PAR)
[22–24]. TLR is recognized as one of the receptors of
PAMPs and DAMPs on microorganisms (Table 1). To
fully appreciate multiple organ failure associated with
SIRS, it is necessary to know which cell types in normal
organs express these inflammatory receptor signals, how
they are distributed, and how their levels change over
the course of SIRS progression. Furthermore, while the
early phase inflammatory alarm in response to foreign
agents in major organs is carried out by alert cells [12, 25],
these cells also increase in number due to SIRS complica-
tion or sustained inflammation. Alert cells express inflam-
matory receptors on their surface and in their cytoplasm
and are characterized by the existence of intracellular
signaling pathways of these inflammatory receptors.
Although vascular endothelial cells may be histologically
related, all of them do not have the same biochemical
capacity to evoke inflammation under normal conditions
as alert cells. While some are sensitive to PAMPs and
cytokines, others are not. The histologically related but
biochemically distinct cells coexist in the same tissue in
major organs including vascular endothelium. When
inflammatory stimulation is emerged in response to bac-
terial infection, the number of alert cells with inflamma-
tory signal increases, thereby accelerating inflammation in
major organs.
Transcription factor activation in SIVA
Overproduction of inflammatory cytokines and mediators
in SIRS and sepsis results from a combination of inflam-
matory receptor activation by PAMPs and DAMPs and
increased messenger RNA (mRNA) production of acute
phase response protein [11, 12, 25]. Mechanisms of NF-
κB and AP-1 activation have become elucidated in acute
phase response and provide a basis for the overproduction
of mRNA of acute phase molecules associated with
systemic inflammation. The intracellular signaling path-
ways of the two transcription factors in vascular endothe-
lial cells are depicted in Fig. 2.
In the response, TLR and IL-1R activate TNF-R-
associated factor 6 (TRAF6) and tumor growth factor-β-
associated kinase 1 (TAK1) via adapter proteins such as
myeloid differentiation factor 88 (MyD88) and interleukin-
1 receptor-associated kinase (IRAK), especially ILAK1 and
ILAK2/4 in vascular endothelial cells. The input signals for
this phosphorylation cascade are TLR2 for lipoteichoic
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acid, TLR4 for LPS, and TLR5 for bacterial flagellin, shown
as Table 1. TNF-α and IL-1β are produced during inflam-
mation and hypoxia in the perioperative period and
induced similar inflammatory signals as SIRS in alert cells
via the respective receptors. As a result, these inflammatory
signals induce phosphorylation of the inhibitory-κB (I-κB)
kinase (IKK) complex, leading to increased nuclear trans-
location of NF-κB as the canonical pathway (Fig. 2). NF-κB
decoy oligonucleotides reduced inflammation in several
tissues in septic mouse study [26–28]. As with NF-κB,
AP-1 activity increases in response to mitogen-activated
protein kinase (MAPK) activation. Activated via TAK1,
MAPK kinase (MAPKK) phosphorylates Jun and Fos fam-
ily members, which then bind to AP-1 and CRE sites in
target promoters.
Such activation of NF-κB and AP-1 occurs in alert
cells of various organs, including vascular endothelial
cells, type II alveolar epithelial cells, right atrial cells,
renal tubular epithelial cells, and intestinal epithelial
cells. In addition to being involved in the NF-κB and
AP-1 activation pathway via TNF receptor-associated
death domain protein (TRADD), TNF-R can activate
death signals via Fas-associated death domain (FADD) in
a pathway distinct from TLR and IL-1R in Fig. 3. Alert
cells undergo autophagy and apoptosis via increased death
receptor (DR) signaling after producing inflammatory me-
diators to alert surrounding cells in response to inflamma-
tory signals [29–31]. When alert cells increase, and the
rate of apoptosis increases relative to that of proliferation,
the number of cells that comprise major organs decreases.
This subsequently leads to intensification of multiple
organ failure. In this context, fibroblast begins to lead to
scarring and restriction in organ tissue because of no
negative control from alert cells. Fibroblast can be acti-
vated into myofibroblasts by adrenergic beta stimulation
and thrombin exposure in SIVA.
NF-κB activation in alert cells
NF-κB is a collective term for the Rel/NF-κB family,
which contains a domain homologous to the proto-
oncogene c-rel. The Rel/NF-κB family comprises RelA
(p65), RelB, c-Rel, NF-κB1 (p105/p50), and NF-κB2
Table 1 Toll-like receptor ligands
TLR subtype PAMPs DAMPs
TLR1 (w/TLR2) triacyl lipoprotein n.d.










TLR5 Flagellin n. d.






TLR9 DNA, hemozoin DNA (immune complex)








Fig. 1 TLR4 expression in the lung, the right atrium, and the atrial septum. The figure is an immunohistochemical staining of Toll-like receptor 4
(TLR4) in the right lower lung (a), right atrium (b), and atrial septum (c) in 12-week-old male BALB-C mice. TLR4 expressed at alveolar type 2 cells,
vascular endothelial cells in lung and in cardiomyocytes and vascular endothelial cells in right atrium, and the endocardium of the atrial septum
by the stain of 3,3′-diaminobenzidine and tetrahydrochloride with anti-TLR4 antibody. Bar: 100 μm


































Fig. 2 Intracellular signal transduction of inflammatory receptors in alert cells in SIVA. In SIRS-associated vasculitis (SIVA), vascular endothelial cells
have an intracellular signal transduction to activate transcriptional factors through inflammatory receptors. Nuclear factor-κB (NF-κB) and activator
protein-1 (AP-1) were activated in alert cells of vascular endothelial cells and lead to produce inflammatory mRNA. TNF-R1 tumor necrosis factor
receptor, MyD88 myeloid differentiation factor 88, IRAK interleukin-1 receptor-associated kinase, TRAF tumor necrosis factor (TNF) receptor-
associated factor, TAK1 TGF-β-activated kinase 1, JNK c-Jun N-terminal kinase, ERK extracellular signal-regulated kinase, MAPK mitogen-activated protein
kinase, IKK inhibitory κB kinase, NEMO NF-κB essential modulator, I-κB inhibitory-κB, TRADD TNF receptor-associated death domain, FADD Fas-associated




















Fig. 3 The death receptor signaling in SIVA. Death receptors (DR) signal is present also in alert cells of the major organs and vasculature in
SIRS-associated vasculitis (SIVA) including sepsis. TNF-R1, Fas (CD95), DR4 (TRAIL receptor 1), and DR5 (TRAIL receptor 2) have a death signal in
alert cells via adaptor molecules of TRADD and FADD. On the other side, TNF-R1 produces the anti-apoptotic factors such as FLIP and BclX via
activation of NF-κB through RIP1-TRAF pathway. When NF-κB activity decreases and AP-1 activity increases, DR family and FADD tend to proceed
apoptosis in alert cells in vascular endothelium. TNF-R1 tumor necrosis factor receptor 1, TRADD TNF receptor-associated death domain protein,
RIP1 receptor-interacting protein 1, IKK inhibitory-κB kinase, TRAF tumor necrosis factor receptor-associated factor, FADD Fas-associated death
domain protein, NF-κB nuclear factor-κB, FLIP FLICE inhibitory protein
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(p100/p52) [32]. These five subunits can homo- or
heterodimerize and are prevented in cytoplasm from
binding to DNA through interactions with inhibitory κB
(I-κB) proteins (i.e., I-κBα, I-κBβ, I-κBε, I-κBγ, I-κBζ,
Bcl-3, p105, p100). NF-κB activation occurs through
canonical and non-canonical pathways.
TLR signaling in response to infection or inflammation
amplifying signals of IL-R and TNF-R ultimately converge
on I-κB kinase (IKK) complex phosphorylation and the
subsequent decrease in cytoplasmic I-κB levels. The IKK
complex exists in the cytoplasm as a large complex of over
700 kDa and is composed of a trimer of IKKα, IKKβ, and
IKKγ/NF-κB essential modulator (NEMO). When acti-
vated, IKKα phosphorylates serines 32 and 36 of I-κBα
and IKKβ phosphorylates serines 19 and 23 of I-κBβ.
NEMO can be activated by both phosphorylation and ubi-
quitination. Upon IKK complex activation and subsequent
I-κB phosphorylation, I-κB is poly-ubiquitinated and tar-
geted for proteasome-mediated degradation. The NF-κB
dimer is then liberated from the inhibitory complex and
translocates into the nucleus, where it binds to its cognate
target sequence (GGGACTTTCC) and transcriptionally
induces inflammatory cytokines and apoptosis inhibiting
factors via the canonical pathway. Signaling through TLR
and IL-R also uses the canonical pathway and results in
nuclear translocation of the RelA and p50 dimer.
On the other side, a non-canonical NF-κB pathway exists
in leukocytes and epithelial cells [33]. In this pathway, IKKα
free of NEMO or IKKβ requires phosphorylation by NF-κB
inducing kinase (NIK) to become an active form. When the
RelB-p100 dimer gets to be phosphorylated by IKKα, p100
undergoes limited processing and generates a RelB-p52
dimer. This dimer then undergoes nuclear translocation
and activates transcription of NF-κB target genes. Some
studies have shown that the NF-κB dimer is trapped in the
nucleus by I-κBζ [34] and that IKKα can localize to both
the cytoplasm and nucleus [35]. Nuclear I-κBζ gets phos-
phorylated by nuclear IKKα, which likely leads to I-κBζ
degradation and NF-κB activation. Some studies suggest
the possibility that free cytoplasmic RelA can transport IKK
into the nucleus by forming a complex. Nuclear IKK can
then phosphorylate histone H3 associated with chromatin
and increase the transcription of small G proteins and im-
mediate early genes such as Fos and Jun [36]. Given the
lack of a full understanding of the non-canonical pathway,
various aspects will need to be elucidated in vascular endo-
thelium in future research.
Table 2 lists representative proteins that are overpro-
duced as a result of NF-κB activation in SIRS, shock, and
disseminated intravascular coagulation: inflammatory
cytokines such as TNF-α, IL-1, and IL-6; inducible nitro-
gen oxide synthase (iNOS) that produces high levels of ni-
tric oxide (NO); inducible cyclooxygenase-2 (COX2) that
leads to production of prostanoids such as prostacyclin;
granulocyte-macrophage colony-stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF), and
macrophage colony-stimulating factor (M-CSF), which ac-
celerate the move of immature granulocytes and macro-
phages to peripheral and have a protective effect in
vascular endothelial cells; chemokines and adhesion mole-
cules that function in leukocyte migration and infiltration
in vascular endothelium; coagulation molecules von Will-
ebrand factor and tissue factor; and plasminogen activator
inhibitor-1 as fibrinolysis inhibitor. These productions
depend partly on NF-κB activation in SIRS and sepsis. In
order to understand systemic inflammation, it is key to
note that NF-κB activation underlies the generation of
inflammatory cytokines and inflammatory molecules.
Glucocorticoids (e.g., prednisolone, methylprednisolone),
which were conventionally used to reduce inflammation in
rheumatoid arthritis, exert a NF-κB inhibiting effect via
glucocorticoid receptor α (GRα). While inflammatory infil-
tration cells (e.g., monocytes, neutrophils, and lympho-
cytes) express GRα, few expression has been observed on
alert cells of major organs and vascular endothelium [36].
Because alert cells are known to express scavenger recep-
tors such as CLR and LOX-1 on their surface in response
to NF-κB activation, the success rate of gene therapy by
liposome encapsulation markedly increases [25–30]. While
glucocorticoids mainly target cells involved in fresh cell-
mediated immunity, such as immature cells, lymphocytes,
and dendritic cells that express GRα, several types of decoy
oligonucleotide aim to reduce the induction of inflamma-
tion by alert cells (Fig. 4). From this perspective, studies
have shown that while NF-κB decoys effectively reduce in-
flammation in major organs in sepsis, they also induce
apoptosis [25–30]. This cell targeting therapeutic concept
was defined as “alert cell strategy” for vascular endothelial
cells in this article.
Table 2 Inflammatory gene expression after nuclear factor-κB
activation
Proinflammatory cytokines Inflammatory enzymes




Chemokines Intracellular adhesion molecule-1







Eotaxin von Willebrand factor
Gro-α, Gro-β, Gro-γ Tissue factor
ΕΝΑ–78 Plasminogen activator inhibitor-1
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NF-κB activation in SIVA
Apoptosis during the early stages of inflammation is pre-
vented by NF-κB-mediated production of anti-apoptotic
molecules such as FLICE-inhibitory protein (FLIP),
inhibitors of apoptosis (IAPs), and BclX in alert cells
[37, 38]. In SIRS and sepsis, the main factor leading
to apoptosis in vascular endothelial cells is the enhanced
expression of death receptor (DR) family and the down-
stream death adapter proteins [29–31] . As established in-
ducers of apoptosis, TNF-R1, CD95 (Fas), DR4 (TRAIL
receptor 1), and DR5 (TRAIL receptor 2) are expressed
not only in immunocompetent cells but also in major or-
gans and vascular endothelial cells. These DR family mem-
bers form a complex with Fas-associated death domain
(FADD) protein, procaspase-8, procaspase-10, and c-
FLIP to generate the death-inducing signal complex
(DISC) (Fig. 3). Although c-FLIP, which inhibits
procaspase-8 processing, increases in response to NF-
κB activation, it decreases as sepsis progresses due to
the associated reduction in NF-κB activity [37]. The
transcriptional induction of DR family members and
FADD in the lungs and vascular endothelial cells in sepsis
has been confirmed by RT-PCR and Western blot analysis.
The activation of caspase 3 following DISC activation
leads to apoptosis [28–30].
Sepsis can be induced in male BALB-C mice by 6-
mm skin incision and ligating the cecum at 5 or 10
mm from the distal end, followed by cecal puncture
with a 21G or 23G needle in the original method
called a keyhole cecal ligation and puncture (keyhole-
CLP) [27, 29, 31]. These CLP mice die within 2 days
of the procedure and show two peaks of NF-κB acti-
vation at around 10 and 15 h, which is followed by a
progressive decrease in activity. A layer of vascular
endothelial cells is found on the surface of an
approximately five-layered smooth muscle layer of the
mouse aorta, which does not exhibit swelling or
shedding under normal conditions. Yet, as sepsis pro-
gresses, vascular endothelial cells tend to swell and
induce cell death (Fig. 5). In addition to immunocom-
petent cells, alert cells in vascular endothelium are
also affected by autophagy and apoptosis. Caspase
inhibitors, FADD inhibitors, and gene therapy using
siRNAs targeting these factors that aim to reduce
apoptosis following inflammation hold promise as
potential therapies [29–31].
AP-1 activation in SIVA
AP-1 is activated in alert cells under severe conditions as-
sociated with SIRS and sepsis. While AP-1 functions in cell
A B
C D
Fig. 4 Expression of the glucocorticoid receptor in the guinea pig lung. a Glucocorticoid receptor α (FITC-chromogenic). b Vascular endothelium
(anti-von Willebrand factor antibody and Cy3-chromogenic). c The superposition image of a and b. d The superposition image of c and nuclear
staining by Hoechst. Glucocorticoid receptor α was not abundantly expressed in lung vasculature. Bar: 100 μm
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proliferation and differentiation, it also induces excessive
synthesis of catecholamines in the central nervous system
and apoptosis of alert cells in the periphery [39–41].
AP-1 genes consist of four families: Jun, Fos, activating
transcription factor (ATF), and the musculoaponeurotic
fibrosarcoma (MAF) oncogene. Jun homodimers or
Jun/Fos heterodimers recognize and bind to the phorbol
12-O-tetradecanoylphorbol-13-acetate-responsive element
(TPA-responsive element; TRE), and Jun/ATF complexes
bind to the cAMP-responsive element (CRE), leading to
the transcriptional induction of inflammatory markers
(COX-2, ICAM-1), matrix metalloproteinases (MMP-1,
MMP-3, MMP-9), and proteins involved in actin
polymerization (CapG, Ezrin, Krp-1, Mts-1). These signal
transduction are observed not only in vascular endothelial
cells but also in fibroblasts in vascular formation.
MAPK is a serine/threonine kinase comprised of four
subfamilies: extracellular signal-regulated kinase (ERK),
Jun-N-terminal protein kinase (JNK), p38 MAPK, and
ERK5/big MAPK1 (BMK1). In SIVA, MAPK is activated
in response to TAK-1 activation in alert cells. This leads
to the subsequent transcriptional activation of AP-1 tar-
gets. JNK is activated during sepsis and phosphorylates
the N-terminal transcriptional activation domains
(TADs) of Jun family members, such as c-Jun, JunB, and
JunD. ERK phosphorylates the TADs of Fos family mem-
bers, such as c-Fos, FosB, Fra-1, and Fra-2. These phos-
phorylation events induce the heterodimerization of Jun
and Fos family members or stabilize Jun homodimers,
resulting in increased binding to the AP-1 binding site
TRE (TGACTCA). While c-Jun, c-Fos, and FosB have
N-terminal TADs, the TADs of JunB, JunD, Fra-1, Fra-2,
and FosB2 are weak. As such, they are weak AP-1
transcriptional activators. With respect to ATF family
members (e.g., ATF-2, ATF-3, B-ATF), phosphorylation
by JNK or p38MAPK leads to their homodimerization
or heterodimerization with Jun family members and
increased binding to CRE sites (TGACGTCA). AP-1
activation tends to be delayed compared to NF-κB acti-
vation. One likely reason for this is that the temporary
activation of phosphatases that inhibit MAPK (e.g.,
protein phosphatase 2A, protein phosphatase 2C, and
MAPK phosphatase) is carried out by MAPK itself. AP-1
can be considered an exacerbating factor in SIVA that
contributes to increased death signaling in alert cells and
to decrease fibroblast formation.
KLF
Kruppel-like transcriptional factor (KLF) is a transcription
factor of the zinc finger family that has recently gained at-
tention for its role in reducing inflammation in vascular
endothelial cells and inducing endothelial NO synthetase
(eNOS) and thrombomodulin expression in these cells
[42, 43]. KLF2 exhibits anti-inflammatory effects by inhib-
ition of thrombin receptor PAR1 in vascular endothelial
cells [43]. Its role in inhibiting AP-1 and NF-κB activity in
vascular endothelial cells has also been reported [44–48].
In early stages of SIVA, iNOS expression increases in
blood vessels, while eNOS expression decreases [49].
Distributive warm shock results when blood vessels sub-
sequently become dilated and exhibit impaired blood
flow regulation due to shear stress. A potential mechan-
ism that underlies the simultaneous increase in iNOS
and decrease in eNOS involves the nuclear translocation
of NF-κB [25, 49] and the methylation of histone in the
gene promoter region of eNOS [50]. In this mechanism,
A B
C D
Fig. 5 Transmission electron microscope image of a mouse pancreas capillary vessel after cecum ligation and puncture. The figure was a
transmission electron microscope image in septic mouse pancreatic capillaries. A male BALB-C mouse was ligated approximately 5 mm of the
cecal tip and penetrated through by 23G needle (CLPcecum ligation and puncture). a Normal. b Septic 12 h. c, d Septic 24 h. In the time course
after CLP, vascular endothelial cells were bulging and swelling and dropped off the basement membrane of vascular endothelium. Bar: 20 μm
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nuclear transferred NF-κB mediates the overproduction
of iNOS mRNA, as well as histone acetylation, which
consequently leads to a decrease in KLF2 and KLF4 tran-
scripts and eNOS expression. Statins can recover de-
creased eNOS levels in SIVA, and this may be related to
the ability of statins to increase KLF expression in vascular
endothelial cells [43–48]. Statins may have potential appli-
cations in the clinical setting for SIVA management. And
more, mRNA induction of KLF2 and KLF4 as alert cell
strategy may have a protection against SIVA and bring
long term surviving in systemic inflammatory patients.
Molecular markers in SIVA
In cell culture evaluation of vascular endothelial cells
using the human umbilical vein endothelial cell (HUVEC)
and the human pulmonary arterial endothelial cell
(HPAEC), the transcriptional activity was valuable in the
main intracellular signaling molecules after an exposure of
TNFα 100 ng/mL by an inner control of actin mRNA
(Tables 3 and 4). There was a significant deference in
mRNA expression between in HUVEC and in HPAEC in
the time course after TNFα exposure. Enzyme-linked im-
munosorbent assay detects the proteins, which mRNA in-
creased at even 4 h after exposure of TNFα, in the culture
medium. ILAK-1, TNFRSF1A, c-FOS, c-Jun, and ATG12
were abundantly increased and could be detected in the
culture medium of HUVEC and HPAEC. This observation
reveals that there could be a possibility to detect them as a
cytotoxic molecular marker in SIVA. It seems to be worth
to evaluate them in clinical specimens.
On the other hand, a control HUVEC stimulated with
TNFα could be useful to detect circulating endothelial
cells in disseminated intravascular coagulation (DIC)
and SIVA [51]. Normal vascular endothelial cells are
different from inflammatory circulating endothelial cells
in the expression of surface membrane molecules. The
criteria for a detection of circulating vascular endothelial
cells in SIVA need the usage of the vascular endothelial
cells subjected to inflammatory stimuli, such as TNFα.
Table 3 mRNA expression after TNF stimulation in human
pulmonary artery endothelial cells
0 min 15 min 30 min 1 h 4 h 8 h
ATG5 1 0.3 0.3 1.2 0.1 0.2
ATG8 1 4.1 4.5 4.0 5.5 0.6
ATG12 1 6.5 4.9 4.3 6.8 2.2
c-FOS 1 10.3 18.6 6.2 3.1 2.8
c-Jun 1 3.2 8.7 4.4 2.1 0.8
ERK1 1 1.6 1.1 0.6 0.5 0.6
FADD 1 1.8 3.2 3.6 2.8 1.2
ILAK1 1 7.3 12.6 10.3 10.1 2.9
ILAK2 1 2.1 1.8 1.6 1.2 0.5
ILAK4 1 2.2 1.8 1.6 1.4 0.6
MAPK14 1 3.8 3.6 3.1 3.5 1.4
MyD88 1 2.1 1.5 1.3 1.1 0.2
p62 1 5.8 6.8 7.2 6.8 2.1
p65 1 1.1 0.8 0.6 0.4 0.2
RIPK 1 3.3 2.2 1.8 2.4 0.8
STAT3 1 6.3 2.4 2.8 3.3 0.5
TLR2 1 5.8 3.6 5.3 3.6 1.2
TLR4 1 0.7 0.8 0.5 0.6 0.2
TAK1 1 3.8 4.3 3.7 3.6 1.2
TNFRSF1A 1 1.9 2.2 1.9 2.1 1.4
ULK1 1 1.5 1.2 1.3 1.8 0.9
Human pulmonary artery endothelial cells (HPAEC) were observed in the time
course in a separate medium after TNFα 100 ng/mL administration without
steroid and the other anti-inflammatory molecules. At 8 h after TNFα stimulation,
the endothelial cells were observed with shape change and cell death in
approximately 35 %. High expression of mRNA of ATG8, ATG12, ILAK1,
MAPK14, p62, TLR2, and TAK1 were observed in HPAEC through the time course
after TNFα by reverse transcription polymerase chain reaction of the inner control
of actin mRNA
Table 4 mRNA expression after TNF stimulation in human
umbilical vein endothelial cell
0 min 15 min 30 min 1 h 4 h 8 h
ATG5 1 0.5 0.5 0.7 0.3 0.1
ATG8 1 2.3 1.8 2.6 2.1 0.3
ATG12 1 2.2 3.9 3.1 2.2 0.8
c-FOS 1 13.6 22.9 5.3 2.8 1.3
c-Jun 1 4.6 12.5 4.9 1.1 0.8
ERK1 1 1.2 0.8 0.7 1.0 0.5
FADD 1 2.2 3.1 3.8 1.8 1.1
ILAK1 1 8.8 14.2 12.4 11.0 3.9
ILAK2 1 2.1 1.8 1.6 1.2 0.7
ILAK4 1 2.2 1.8 1.6 1.4 0.5
MAPK14 1 4.2 3.4 3.4 3.9 1.5
MyD88 1 2.2 2.1 1.7 2.1 0.3
p62 1 1.3 3.5 9.4 7.7 1.6
p65 1 0.8 1.4 1.4 1.1 0.5
RIPK 1 3.2 2.7 2.2 3.4 0.8
STAT3 1 6.3 2.4 2.8 3.0 0.2
TLR2 1 6.1 2.8 5.3 2.6 0.4
TLR4 1 1.6 1.3 1.7 1.5 0.2
TAK1 1 2.8 3.9 3.1 3.6 0.8
TNFRSF1A 1 12.4 12.1 12.2 12.3 3.1
ULK1 1 3.7 4.7 2.9 5.1 1.8
Human umbilical vein endothelial cells (HUVEC) were observed in the time
course in a separate medium after TNFα 100 ng/mL administration without
steroid and the other anti-inflammatory molecules. At 8 h after TNFα stimulation,
the endothelial cells were observed with shape change and cell death in
approximately 32 %. High expression of mRNA of ILAL1, p62, TNFRF1A, and ULK
were observed in HUVEC through the time course after TNFα by reverse transcription
polymerase chain reaction of the inner control of actin mRNA
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This element could be one of the detecting systems in a
progression of SIVA. Endothelial cell injury and the
detachment from basement membrane would induce the
two aspects of “warm shock” and “cold shock” in the
microcirculation [52]. Clinical evaluation of long-term
prognosis for the complication of SIVA seems to be one
of the topics for future research.
Conclusions
This article approached the topic of multiple organ dys-
function and DIC in SIRS and sepsis from the viewpoint
of transcription activity of mRNA in vasculature as
SIVA. Inflammation is exacerbated by the increased re-
sponse of alert cells in vascular endothelium with sepsis
progression. Major organs become impaired in function
of alert cells as increasing cell death. In vasculature,
endothelial cell death would change “warm shock” to
“cold shock” in septic shock. Enough blood flow would
be impaired in organs. A theory of rescuing alert cells
from inflammation and cell death during and following
inflammation is called the alert cell strategy. DR signal-
ing and the transcriptional regulation are likely to
become a crucial target of vascular resuscitation in pro-
longed sepsis management.
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